Seres Therapeutics, Inc. (MCRB): Capital Expenditures
$252.0K
Year ended 2025-12-31
$37.0K
Trailing 12 months to 2026-06-30
-70.5%
3-year compound annual growth
-15.7%
5-year compound annual growth
-24.8%
10-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $252.0K | -33.7% | 2026-03-12, From 2025-01-01 |
| 2024-12-31 | $380.0K | -95.2% | 2026-03-12, From 2024-01-01 |
| 2023-12-31 | $7.97M | -18.8% | 2026-03-12, From 2023-01-01 |
| 2022-12-31 | $9.82M | +2.7% | 2025-03-13, From 2022-01-01 |
| 2021-12-31 | $9.57M | n/m | 2024-03-05, From 2021-01-01 |
| 2020-12-31 | $591.0K | -41.0% | 2023-03-07, From 2020-01-01 |
| 2019-12-31 | $1.00M | -48.3% | 2022-03-01, From 2019-01-01 |
| 2018-12-31 | $1.94M | -58.6% | 2021-03-02, From 2018-01-01 |
| 2017-12-31 | $4.68M | -78.2% | 2020-03-02, From 2017-01-01 |
| 2016-12-31 | $21.49M | +392.7% | 2019-03-06, From 2016-01-01 |
| 2015-12-31 | $4.36M | +335.8% | 2018-03-08, From 2015-01-01 |
| 2014-12-31 | $1.00M | +475.3% | 2017-03-16, From 2014-01-01 |
| 2013-12-31 | $174.0K | n/a | 2016-03-14, From 2013-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Seres Therapeutics, Inc. (MCRB) | 2025-12-31 | $252.0K | -33.7% |
| Elite Pharmaceuticals Inc (ELTP) | 2026-03-31 | $925.6K | -43.0% |
| Prelude Therapeutics Inc (PRLD) | 2025-12-31 | $67.0K | -91.2% |
| Silence Therapeutics plc (SLN) | 2025-12-31 | $55.0K | -73.9% |
| Larimar Therapeutics, Inc. (LRMR) | 2025-12-31 | $91.0K | -82.3% |
| Acrivon Therapeutics, Inc. (ACRV) | 2025-12-31 | $1.67M | -39.7% |
| XBiotech Inc. (XBIT) | 2025-12-31 | $289.0K | -77.8% |
| Zomedica Corp. (ZOMDF) | 2025-12-31 | $567.0K | -89.1% |
| Whitehawk Therapeutics, Inc. (WHWK) | 2025-12-31 | $552.0K | -66.6% |
Compare MCRB, ELTP, PRLD, SLN side by side · Screen every company in Pharmaceutical Preparations ↗